• The skin is our largest organ.

    The skin is unique in many ways, but no other organ is so visible and demands so much attention and care in both diseased and healthy states.

About us

Dermaliq Therapeutics, Inc., is a private pharmaceutical company with a therapeutic focus on dermatology, founded in 2021 through a spin-off from Novaliq GmbH.

Our mission is to develop a new generation of premium topical therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. Our unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability and stability for many active ingredients combined with a cosmetic acceptability that was previously hard to achieve for topically applied drugs..

THERAPEUTICS FOCUS

Dermatology

Skin disorders and diseases are the fourth leading cause of nonfatal disease burden worldwide, underscoring the importance of dermatology in the field of global health. Skin conditions have significant impact on patients’ well-being, mental health, ability to function, and social participation.
Dermatological treatments are largely divided into external application of drugs (topical therapies), systemic therapies (oral administration or injections of drugs or biologics), physical therapies (for example, light and climate therapies), and laser or surgical therapies. Among these treatments, topical and localized delivery of active ingredients to the diseased skin is the preferred route of treatment in a majority of patients, reducing the risk of systemic side effects.

  • therapeutics focus
  • focus on disease

Technology

The evolutionary hyliQTM– technology

hyliQTM, the unique and proprietary technology owned by Dermaliq, is designed to provide cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives.

The technology enables the development of superior liquid drug products which are characterized by exceptional cosmetic properties.

hyliQTM products are water-free, and do not require preservatives or additional penetration enhancers.

  • technology
  • technology

How it works

Proprietary hyliQTM carrier molecules transport solubilized active ingredients through the stratum corneum, preferably into the epidermis, into glands, or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues and reducing unwanted side effects.

dermaliq skin
hyliQTM – drug candidates

full dose is absorbed into skin and glands

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

  • Stratum Corneum

  • Epidermis

  • Dermis

  • Subcutaneous Tissue

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

  • Stratum Corneum

  • Epidermis

  • Dermis

  • Subcutaneous Tissue

Our Pipeline

Our goal is to establish a comprehensive pipeline of next-generation topical drugs and skin care products based on our proprietary hyliQTM technology.
DLQ01
  • Androgenetic Alopecia
    DLQ01 is a novel topical formulation with a prostaglandin (PG) F2alpha analog intended to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. Our IP protected drug candidate is delivered by hyliQTM as a liquid solution. We plan to initiate a Phase 1/2a safety and efficacy trial in men with androgenic alopecia in Q3 2022.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Androgenetic Alopecia
    DLQ01 is a novel topical formulation with a prostaglandin (PG) F2alpha analog intended to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. Our IP protected drug candidate is delivered by hyliQTM as a liquid solution. We plan to initiate a Phase 1/2a safety and efficacy trial in men with androgenic alopecia in Q3 2022.

DLQ01

DLQ02
  • Plaque Psoriasis
    DLQ02 is a unique, liquid hyliQTM based formulation of a calcineurin inhibitor for topical therapy of plaque psoriasis. This drug candidate is particularly well suited for difficult-to-treat body areas such as the palms and feet, nails, face, scalp, and genital areas.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Plaque Psoriasis
    DLQ02 is a unique, liquid hyliQTM based formulation of a calcineurin inhibitor for topical therapy of plaque psoriasis. This drug candidate is particularly well suited for difficult-to-treat body areas such as the palms and feet, nails, face, scalp, and genital areas.

DLQ02

DLQ03
  • Bacterial soft tissue and skin infections
    DLQ03 is a broad-spectrum liquid antibiotic drug candidate designed for topical treatment of Bacterial skin and soft tissue infections (SSTIs), including the reduction of antibiotic-resistant strains. SSTIs are frequent and cases involving antibiotic resistant strains can be difficult to treat and even life-threatening. We plan to initiate a Phase 1 safety, tolerability, and antibacterial effectiveness study in Q2/Q3 2022.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Bacterial soft tissue and skin infections
    DLQ03 is a broad-spectrum liquid antibiotic drug candidate designed for topical treatment of Bacterial skin and soft tissue infections (SSTIs), including the reduction of antibiotic-resistant strains. SSTIs are frequent and cases involving antibiotic resistant strains can be difficult to treat and even life-threatening. We plan to initiate a Phase 1 safety, tolerability, and antibacterial effectiveness study in Q2/Q3 2022.

DLQ03

Our Professionals

Our team of seasoned industry experts explores the world of hyliQTM based therapies to develop best-in-class therapies for skin care.

Management

Dr. Frank Löscher

CEO, President and co-founder

Betsy Hughes-Formella, PhD

CSO and co-founder

Dr. Oliver Schlüter

CFO and co-founder

Contact us

Contact Form